Ann O’Callaghan
A5027645258- Colorectal Cancer Treatments and Studies
- Radiomics and Machine Learning in Medical Imaging
- Cancer Treatment and Pharmacology
- Medical Imaging Techniques and Applications
- Cancer Immunotherapy and Biomarkers
- SARS-CoV-2 and COVID-19 Research
- Immunotherapy and Immune Responses
- CAR-T cell therapy research
- Lymphoma Diagnosis and Treatment
- COVID-19 Clinical Research Studies
- Lung Cancer Treatments and Mutations
- Gastric Cancer Management and Outcomes
- COVID-19 and healthcare impacts
- Multiple and Secondary Primary Cancers
- Radiopharmaceutical Chemistry and Applications
- Gastrointestinal disorders and treatments
- Myasthenia Gravis and Thymoma
- Monoclonal and Polyclonal Antibodies Research
- Colorectal and Anal Carcinomas
- Hepatocellular Carcinoma Treatment and Prognosis
- Lymphatic Disorders and Treatments
- Urinary and Genital Oncology Studies
- Systemic Lupus Erythematosus Research
- Infection Control and Ventilation
- Chemotherapy-induced cardiotoxicity and mitigation
Portsmouth Hospitals NHS Trust
2016-2023
National Health Service
2023
Queen Alexandra Hospital
2013-2023
Wellcome Trust
2023
St James's University Hospital
2023
Sheffield Teaching Hospitals NHS Foundation Trust
2020
Birkbeck, University of London
2019
Ludwig-Maximilians-Universität München
2018
LMU Klinikum
2018
St Mary's Hospital
2003
BackgroundTherapeutic antibodies targeting EGFR have activity in advanced colorectal cancer, but results from clinical trials are inconsistent and the population which most benefit is derived uncertain. Our aim was to assess addition of panitumumab irinotecan pretreated cancer.MethodsIn this open-label, randomised trial, we enrolled patients who had cancer progressing after fluoropyrimidine treatment with or without oxaliplatin 60 centres UK. From December, 2006 until June, 2008, molecularly...
BackgroundThe interim analysis of the multicentre New EPOC trial in patients with resectable colorectal liver metastasis showed a significant reduction progression-free survival allocated to cetuximab plus chemotherapy compared those given alone. The focus present was assess effect on overall survival.MethodsNew multicentre, open-label, randomised, controlled, phase 3 trial. Adult (aged ≥18 years) KRAS wild-type (codons 12, 13, and 61) or suboptimally metastases WHO performance status 0–2...
Abstract Patients with hematological malignancies are at increased risk of severe COVID-19 outcomes due to compromised immune responses, but the insights these studies have been intrinsic limitations in study design. Here we present PROSECO prospective observational ( NCT04858568 ) on 457 patients lymphoma that received two or three vaccine doses. We show undetectable humoral responses following doses 52% undergoing active anticancer treatment. Moreover, 60% anti-CD20 therapy had antibodies...
Pre-clinical models demonstrate that platelet activation is involved in the spread of malignancy. Ongoing clinical trials are assessing whether aspirin, which inhibits activation, can prevent or delay metastases.
We have clinically evaluated a DNA fusion vaccine to target the HLA-A*0201-binding peptide CAP-1 from carcinoembryonic antigen (CEA
3523 Background: Phase III trials show inconsistent effects when anti-EGFR drugs are added to cytotoxic therapy in aCRC. Benefits, present, confined patients (pts) determined retrospectively have KRAS wild-type (wt) tumours. PICCOLO is a multicentre randomized controlled trial, amended June 2008 include prospective testing, evaluate the addition of panitumumab (Pan) single-agent irinotecan (Ir) as second- or subsequent-line for KRAS-wt Methods: Eligible pts had: measurable aCRC progressing...
Conference Article| June 01 1984 Possible biochemical basis for bilirubin neurotoxicity ANN O'CALLAGHAN; O'CALLAGHAN *Biochemistry Department, University College, Cork and Biochemistry Laboratory, Regional Hospital, Cork, Ireland Search other works by this author on: This Site PubMed Google Scholar P. FINBARR DUGGAN ‡ †Biochemistry ‡To whom correspondence should be addressed. Biochem Soc Trans (1984) 12 (3): 483. https://doi.org/10.1042/bst0120483 Views Icon Article contents Figures & tables...
Advanced or metastatic disease is common in both oesophagogastric and colorectal cancers, with poor 5-year survival despite palliative chemotherapy. We have investigated the sensitivity of gastrointestinal tumours to gemcitabine combination mitomycin C (GeM), using a modified ex vivo ATP-based tumour chemosensitivity assay (ATP-TCA). Tumour material from 41 22 cancers were assessed. The GeM showed variable but definite activity most samples tested. results show that achieves >95% inhibition...
2579 Background: We have designed DNA fusion vaccines encoding a tumor-derived peptide, linked to tolerance-breaking domain sequence (DOM) from tetanus toxin. One peptide prostate cancer is in clinical trial with CD8+ T-cell responses detected 60% of patients. For patients CEA expressing cancers, the target an HLA-A2-binding sequence, CAP-1 (CEA605–613). Methods: undertook single dose level, two-arm phase I/II study examine safety and immunogenicity vaccine (p.DOM-CAP-1) CEA-expressing...
Introduction: EZH2, a histone methyl transferase subunit of Polycomb repressor complex 2, is frequently mutated in DLBL. Inhibitors EZH2 have demonstrated promising responses early clinical trials. We examined the frequency mutation 2 large prospective series DLBL and correlated this to outcomes relation other biological features. Methods: Patients (pts) received standard immunochemotherapy regimens as first-line treatment for Sanger sequencing (SS) focusing on “hotspot” sites exons 16 18...
Abstract: Antisera against 2‐aminoimipramine covalently coupled to albumin have been raised in two rabbits. Both antisera bind imipramine and related tricyclic compounds as if a single class of sites with high affinity litres. Displacement/inhibition assays showed that the affinities various for good correlation these drugs antidepressant inhibitory on plasma‐membrane 5‐hydroxytryptamine carriers human platelets rat brain cortex. 5‐Hydroxytryptamine 5‐hy‐droxytryptamine‐uptake‐selective did...
Abstract Individuals with lymphoid malignancies have an increased mortality risk from COVID-19. Paradoxically, this population is least likely to be protected by SARS-CoV-2 vaccination as a result of disease- or treatment-related immunosuppression. Current data on vaccine responses in persons limited. PROSECO UK multi-centre prospective observational study evaluating COVID-19 immune individuals lymphoma. This early interim analysis details the antibody first- and second-SARS-CoV-2 either...
<p>Scatterplot: AREG vs EREG</p>
<p>Example AREG and EREG immunohistochemistry</p>